The ANKMY2 antibody targets the ANKMY2 protein, a member of the ankyrin repeat-containing protein family, characterized by its conserved ankyrin repeat motifs and a MYND (Myeloid-Nervy-DEAF1) domain. ANKMY2 is implicated in diverse cellular processes, including intracellular signaling, protein-protein interactions, and transcriptional regulation. While its precise biological role remains under investigation, studies suggest its involvement in neural development, cancer progression, and DNA damage response pathways. For instance, ANKMY2 has been linked to the regulation of nuclear factor-kappa B (NF-κB) signaling and the stability of MYCN, a critical oncoprotein in neuroblastoma.
The ANKMY2 antibody is widely used in research to detect and quantify ANKMY2 expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Its specificity is validated through knockdown/knockout controls or epitope-tagged protein assays. Commercially available antibodies are typically raised in hosts such as rabbits or mice, with variations in clonality (monoclonal/polyoclonal) and conjugation (e.g., HRP, fluorescent tags). Researchers employ this tool to explore ANKMY2's roles in diseases, particularly cancers like glioblastoma and neuroblastoma, where altered expression levels correlate with tumor aggressiveness or patient prognosis. Ongoing studies aim to clarify its molecular mechanisms and therapeutic potential.